Striatal uptake of a novel PET ligand, [18F]β-CFT, is reduced in early Parkinson's disease

Synapse

Volumn 31, Issue 2, 1999, Pages 119-124

  Rinne, J O ^a   Bergman, J ^b   Ruottinen, H ^a   Haaparanta, M ^c   Eronen, E ^d   Oikonen, V ^d   Sonninen, P ^a   Solin, O ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b Accelerator Laboratory   (Finland)

^c TURKU PET CENTRE   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

CFT; Dopamine; Dopamine reuptake; Parkinson's disease; PET; Positron emission tomography

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CEREBELLUM; CLINICAL ARTICLE; DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PUTAMEN;

AGED; ANIMALS; CAUDATE NUCLEUS; COCAINE; DOPAMINE UPTAKE INHIBITORS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032919523     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199902)31:2<119::AID-SYN4>3.0.CO;2-O     Document Type: Article

References (39)

1. 3H]GBR-12935 binding to dopamine uptake sites is decreased in Parkinson's disease and dementia of the Alzheimer type. Brain Res 637:262-266.
2. Aquilonius SM, Bergstrom K, Eckernäs S-Å, Hartvig P, Leenders K, Lundqvist H, Antoni G, Gee A, Rimland A, Uhlin J, Långström B. 1987. In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand 76:283-287.
3. 18F]fluoride. J Nucl Med 34:69P
4. Boja JW, Cline EJ, Carroll FI, Lewin AH, Philip A, Dannals R, Wong D, Scheffel U, Kuhar MJ. 1992. High potency cocaine analogs: Neurochemical, imaging and behavioral studies. Ann NY Acad Sci 654:282-291.
5. Brooks DJ. 1993. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 115:1-17.
6. Brooks DJ. 1997. Advances in imaging Parkinson's disease. Curr Opin Neurol 10:327-331.
7. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RSJ. 1990. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease, studied with PET. Brain 113:1539-1552.
8. Fahn S, Elton RL, and the members of the UPDRS Development Committee. 1987. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, Vol. II. Florham Park, NJ: Macmillan, pp 153-163.
9. Fearnley J, Lees AJ. 1991. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114:2283-2301.
10. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 43:423-431.
11. Garnett ES, Nahmias C, Firnau G. 1984. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 11:174-179.
12. Goto S, Hirano A, Matsumoto S. 1989. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 26:766-770.
13. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: Biodistribution in rats. Synapse 23:321-327.
14. 3H]raclopride. J Neural Transm 73:7-21.
15. Hornykiewicz O. 1993. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system - Possible neurochemical mechanisms. Adv Neurol 60:140-147.
16. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. 1992. What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathological study. Neurology 42:1142-1146.
17. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D. 1996. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/ SPECT and fluorine-18-FDOPA/PET. J Nucl Med 37:1760-1765.
18. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 49:617-621.
19. Kish SJ, Shannak K, Hornykiewicz O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications. N Engl J Med 318:876-880.
20. Kuhar MJ, Sanchez-Roa PM, Wong DF, Dannals RF, Grigoriadis DE, Lew R, Milberger M. 1990. Dopamine transporter: Biochemistry, pharmacology and imaging. Eur Neurol 30(suppl):15-20.
21. 11C]β-CIT in Parkinson's disease. J Nucl Med 36:1263-1267.
22. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T. 1986. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49:853-860.
23. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RSJ. 1990. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47:1290-1298.
24. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. 1996. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data. J C GRGB Blood Flow Metab 16:834-840.
25. 3H]GBR-12935 binding to dopamine uptake sites: Subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 156:331-340.
26. 125I]iodosulpiride, a highly selective ligand. Science 228:752-754.
27. Moore RY, Blood FE. 1978. Central catecholamine neuron systems: Anatomy and physiology of the dopamine systems. Annu Rev Neurosci 1:129-169.
28. Pellizari CA, Chen GTY, Spelbring DR, Weichselbaum RR, Chen CT. 1989. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. J Comput Assist Tomogr 13:20-26.
29. 3H]cocaine binding to the dopamine transporter in Parkinson's disease. Eur J Pharmacol 95:145-146.
30. Rakshi JS, Bailey DL, Ito K, Uema T, Morrish PK, Fristen KJ, Brooks DJ. 1997. Methodology for statistical parametric mapping of [18F]-fluorodopa uptake rate using 3D PET. Neuroimage 5:B19.
31. Rinne UK, Sonninen V. 1973. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Arch Neurol 28:107-110.
32. Rinne JO, Rummukainen J, Paljärvi L, Rinne UK. 1989. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26:47-50.
33. 11C]β-CFT in early Parkinson's disease. Synapse 21:97-103.
34. 3H-nomifensine binding sites in rat brain. Life Sci 36:815-822.
35. - (aq.). J Label Compoun Radiopharm 32:137-138.
36. Spinks TJ, Jones T, Gilardi MC, Heather JD. 1988. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Med 35:721-725.
37. 11C-nomifensine and positron emission tomography: The effects of age and Parkinson's disease. Acta Neurol Scand 77:192-201.
38. 6F-fluorodopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 81:24-30.
39. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K, Niznik HB, Hornykiewicz O, Pifl C, Kish SJ. 1996. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47:718-726.